{"transactions":[{"id":2140987,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:15:29.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":28628,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":29.87,"underlying":"Common Stock","underlying_shares":28628},"source":{"system":"sec-edgar","filing":"0000899243-22-033146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033146/doc4.xml","form_type":"4"}},{"id":2140986,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-06T16:15:29.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":49600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, an \"Issuer Stock Option\"), whether vested or unvested, was canceled in exchange for the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such Issuer Stock Option immediately prior to the Effective Time multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of such Issuer Stock Option."}],"balance_after":0,"derivative":{"exercise_price":29.85,"underlying":"Common Stock","underlying_shares":49600},"source":{"system":"sec-edgar","filing":"0000899243-22-033146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033146/doc4.xml","form_type":"4"}},{"id":2140985,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:15:29.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":42400,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Each outstanding PSU tied to a price hurdle with respect to a share of Common Stock (and not relative total shareholder return) was forfeited at the Effective Time."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":42400},"source":{"system":"sec-edgar","filing":"0000899243-22-033146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033146/doc4.xml","form_type":"4"}},{"id":2140984,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:15:29.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":26454,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding PSU was canceled and converted into the right to receive an amount in cash equal to (i) (x) with respect to a PSU subject to vesting based on the Issuer's relative total shareholder return, approximately 199.5% of the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time and (y) with respect to a PSU subject to vesting based on the Issuer's relative percentage of patient share, the target number of shares of Common Stock subject to such PSU immediately prior to the Effective Time, in each case multiplied by (ii) the Merger Consideration. Includes 8,786 additional shares of Common Stock deemed vested as of immediately prior to the Effective Time in accordance with the preceding sentence."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":26454},"source":{"system":"sec-edgar","filing":"0000899243-22-033146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033146/doc4.xml","form_type":"4"}},{"id":2140983,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:15:29.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":15460,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15460},"source":{"system":"sec-edgar","filing":"0000899243-22-033146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033146/doc4.xml","form_type":"4"}},{"id":2140982,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2022-10-06T16:15:29.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":24180,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each (i) restricted stock unit of the Issuer subject only to service-based vesting requirements (\"RSU\") and (ii) restricted stock unit of the Issuer subject to performance-based vesting requirements (\"PSU\") represented a contingent right to receive one share of Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, subject to all required withholding taxes, each outstanding RSU was canceled and converted into the right to receive an amount in cash equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the completion of the Merger multiplied by (ii) the Merger Consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24180},"source":{"system":"sec-edgar","filing":"0000899243-22-033146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033146/doc4.xml","form_type":"4"}},{"id":2140981,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2022-10-06T16:15:29.000Z","date":"2022-10-05","kind":"disposition_to_issuer","acquired":false,"shares":6716,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 7, 2022, by and among the Issuer, Pfizer Inc., a Delaware corporation (\"Parent\"), and Ribeye Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of the effective time of the Merger (the \"Effective Time\") on October 5, 2022. At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share (\"Common Stock\"), reported in this Form 4 was converted into the right to receive $68.50 in cash (the \"Merger Consideration\"), without interest and subject to any required tax withholding, upon the terms and subject to the conditions of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033146","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322033146/doc4.xml","form_type":"4"}},{"id":2165011,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2022-09-06T19:00:31.000Z","date":"2022-09-01","kind":"exercise","acquired":false,"shares":2208,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":15460,"derivative":{"underlying":"Common Stock","underlying_shares":2208},"source":{"system":"sec-edgar","filing":"0000899243-22-030477","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030477/doc4.xml","form_type":"4"}},{"id":2165010,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2022-09-06T19:00:31.000Z","date":"2022-09-01","kind":"exercise","acquired":false,"shares":8060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest with respect to 25% of the underlying shares on September 1, 2022 and in 6 semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest with respect to 25% of the underlying shares on September 1, 2022 and in 6 semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":24180,"derivative":{"underlying":"Common Stock","underlying_shares":8060},"source":{"system":"sec-edgar","filing":"0000899243-22-030477","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030477/doc4.xml","form_type":"4"}},{"id":2165009,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2022-09-06T19:00:31.000Z","date":"2022-09-01","kind":"tax_withholding","acquired":false,"shares":3552,"price":68.15,"value":242068.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 10,268 shares of Common Stock underlying the Reporting Person's RSUs."}],"balance_after":6716,"source":{"system":"sec-edgar","filing":"0000899243-22-030477","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030477/doc4.xml","form_type":"4"}},{"id":2165008,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2022-09-06T19:00:31.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":2208,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":10268,"source":{"system":"sec-edgar","filing":"0000899243-22-030477","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030477/doc4.xml","form_type":"4"}},{"id":2165007,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Common Stock","published_at":"2022-09-06T19:00:31.000Z","date":"2022-09-01","kind":"exercise","acquired":true,"shares":8060,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."}],"balance_after":8060,"source":{"system":"sec-edgar","filing":"0000899243-22-030477","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322030477/doc4.xml","form_type":"4"}},{"id":2352632,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2022-03-03T21:02:53.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":28628,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares of Common Stock underlying the stock option vest in 16 equal quarterly installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":28628,"derivative":{"exercise_price":29.87,"expiration_date":"2032-02-28","underlying":"Common Stock","underlying_shares":28628},"source":{"system":"sec-edgar","filing":"0000899243-22-009249","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322009249/doc4.xml","form_type":"4"}},{"id":2352631,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-03T21:02:53.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":17668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The shares of Common Stock underlying the RSUs vest in two installments, if at all, based on (i) the Issuer's total shareholder return percentile ranking relative to the companies in the NASDAQ Biotechnology Index for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date, and (ii) the percentage of patient share relative to a comparator group for a three-year cumulative performance period commencing January 1, 2022 and ending December 31, 2024, as affirmed by the Issuer's compensation committee of its board of directors, subject to the Reporting Person's continued service to the Issuer through such date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":17668,"derivative":{"underlying":"Common Stock","underlying_shares":17668},"source":{"system":"sec-edgar","filing":"0000899243-22-009249","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322009249/doc4.xml","form_type":"4"}},{"id":2352630,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2022-03-03T21:02:53.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":17668,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2022, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":17668,"derivative":{"underlying":"Common Stock","underlying_shares":17668},"source":{"system":"sec-edgar","filing":"0000899243-22-009249","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924322009249/doc4.xml","form_type":"4"}},{"id":2580984,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-02T20:00:29.000Z","date":"2021-09-01","kind":"grant","acquired":true,"shares":49600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests with respect to 25% of the underlying shares on August 2, 2022 and in 12 equal quarterly installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date.  This option is subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":49600,"derivative":{"exercise_price":29.85,"expiration_date":"2031-08-31","underlying":"Common Stock","underlying_shares":49600},"source":{"system":"sec-edgar","filing":"0000899243-21-034986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321034986/doc4.xml","form_type":"4"}},{"id":2580983,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-02T20:00:29.000Z","date":"2021-09-01","kind":"grant","acquired":true,"shares":42400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest in installments conditioned upon the achievement, on or before June 30, 2024, of up to three specified market price thresholds of the Issuer, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":42400,"derivative":{"underlying":"Common Stock","underlying_shares":42400},"source":{"system":"sec-edgar","filing":"0000899243-21-034986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321034986/doc4.xml","form_type":"4"}},{"id":2580982,"issuer":{"id":123220,"kind":"organization","name":"Global Blood Therapeutics, Inc.","symbol":"GBT"},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Restricted Stock Units","published_at":"2021-09-02T20:00:29.000Z","date":"2021-09-01","kind":"grant","acquired":true,"shares":32240,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents the right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest with respect to 25% of the underlying shares on September 1, 2022 and in six semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest with respect to 25% of the underlying shares on September 1, 2022 and in six semi-annual installments thereafter, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer."}],"balance_after":32240,"derivative":{"underlying":"Common Stock","underlying_shares":32240},"source":{"system":"sec-edgar","filing":"0000899243-21-034986","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1629137/000089924321034986/doc4.xml","form_type":"4"}},{"id":2855014,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T02:09:12.000Z","date":"2021-02-12","kind":"grant","acquired":true,"shares":11200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting  Person remains in continuous service as of the applicable vesting dates."}],"balance_after":11200,"derivative":{"exercise_price":16.82,"expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":11200},"source":{"system":"sec-edgar","filing":"0000899243-21-007023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924321007023/doc4.xml","form_type":"4"}},{"id":2906146,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-15T21:30:15.000Z","date":"2021-01-13","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the Vesting Commencement date, provided that the Reporting  Person remains in continuous service as of the applicable vesting dates."}],"balance_after":40000,"derivative":{"exercise_price":13.27,"expiration_date":"2031-01-12","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0000899243-21-002193","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924321002193/doc4.xml","form_type":"4"}},{"id":3028653,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Incentive Stock Option (right to buy)","published_at":"2020-09-18T01:50:06.000Z","date":"2020-09-17","kind":"grant","acquired":true,"shares":40391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares of common stock subject to the option shall vest on each of the forty-eight (48) monthly anniversaries of the vesting commencement date, provided that Ms. Krehlik remains in continuous service as of the applicable vesting date."}],"balance_after":40391,"derivative":{"exercise_price":16.11,"expiration_date":"2030-09-17","underlying":"Common Stock","underlying_shares":40391},"source":{"system":"sec-edgar","filing":"0000899243-20-025644","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924320025644/doc4.xml","form_type":"4"}},{"id":3028652,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-18T01:50:06.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":15450,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Received in exchange for an employee stock option to acquire 124,600 shares of common stock of Old Adicet for $0.740 per share in connection with the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the option vests on each of the forty-eight (48) monthly anniversaries of October 15, 2019, provided that Ms. Krehlik remains in continuous service as of the applicable vesting date."}],"balance_after":15450,"derivative":{"exercise_price":5.97,"expiration_date":"2029-10-15","underlying":"Common Stock","underlying_shares":15450},"source":{"system":"sec-edgar","filing":"0000899243-20-025644","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924320025644/doc4.xml","form_type":"4"}},{"id":3028651,"issuer":{"id":6860,"kind":"organization","name":"Adicet Bio, Inc."},"owners":[{"id":123221,"kind":"person","name":"Krehlik Carrie","position":1,"cik":"0001823899","reported_name":"Krehlik Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Human Resources Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-09-18T01:50:06.000Z","date":"2020-09-15","kind":"grant","acquired":true,"shares":18600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for an employee stock option to acquire 150,000 shares of common stock of Adicet Bio, Inc., a Delaware corporation (\"Old Adicet\"), for $0.280 per share in connection with the merger (the \"Merger\") of Old Adicet with and into Project Oasis Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of resTORbio, Inc., a Delaware corporation (\"resTORbio\").  On the effective date of the Merger, resTORbio changed its name to \"Adicet Bio, Inc.\""},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option vested on November 27, 2018, and 1/36th of the remaining unvested option vests on each of the next thirty-six (36) monthly anniversaries thereafter, provided that Ms. Krehlik remains in continuous service as of the applicable vesting date."}],"balance_after":18600,"derivative":{"exercise_price":2.26,"expiration_date":"2027-12-13","underlying":"Common Stock","underlying_shares":18600},"source":{"system":"sec-edgar","filing":"0000899243-20-025644","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1720580/000089924320025644/doc4.xml","form_type":"4"}}]}